EMR Project on acral lentiginous melanoma (ALM) at EADO 2023
At the EUMelaReg SDAC & IDC Retreat, a project was discussed, which was presented as an e-poster at the EADO congress: “Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibition in the unresectable or metastatic setting – a EUMelaReg real world outcome study.”
Melanoma and other skin cancers are prone to respond to immune checkpoint inhibition (ICI), due to a high tumor mutational burden (TMB), mainly caused by ultraviolet (UV) induced somatic mutations.
Acral lentiginous melanoma (ALM) is a clinico-pathological subtype of cutaneous melanoma. The existing evidence is not finally settled as to whether these patients would benefit from ICI immunotherapies like patients with other cutaneous subtypes. Our study confirms that ALM is a melanoma subtype that responds less well to ICI treatment than other cutaneous melanoma subtypes. Given the fact that treatment alternatives are sparse, in particular since BRAF V600 mutations are rare in ALM, new treatment approaches are urgently needed for patients with advanced ALM.